# CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

> **NCT00056160** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 353 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00056160
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-01
- **Primary completion:** 2005-11-01
- **Final completion:** 2008-10-01
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2017-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056160, "CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00056160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*